AXR 270
Alternative Names: AXR-270; CSP-270Latest Information Update: 28 Oct 2024
At a glance
- Originator AxeroVision
- Developer AxeroVision; CS Pharmaceuticals
- Class Anti-inflammatories; Corticosteroids; Eye disorder therapies; Small molecules
- Mechanism of Action Glucocorticoid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Blepharitis
- Phase I/II Dry eyes
- Phase I Uveitis
- Preclinical Diabetic macular oedema
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Dry-eyes in USA (Ophthalmic, Drops)
- 01 Nov 2023 Phase-I clinical trials in Uveitis (unspecified route) (CS Pharmaceuticals pipeline, November 2023)
- 01 Nov 2023 Preclinical trials in Diabetic macular oedema in United Kingdom (unspecified route) (CS Pharmaceuticals pipeline, November 2023)